|
Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas Clinical research trials and Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas. Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas clinical trial. Test subjects typically obtain the finest healthcare available for their Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas  Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas
Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas
For Condition: Malignant Gliomas,Glioblastoma
Status: Recruiting
Sponsor(s): Celgene Corporation ,
Synopsis: Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Uncontrolled, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Patients with glioblastoma multiforme (GBM), gliosarcoma, anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma (AMO), malignant glioma/astrocytoma NOS (not otherwise specified). Also included will be radiographically diagnosed infiltrating brain stem gliomas not amenable to biopsy. Other CNS tumor histologies will not be eligible for this trial. - Patients must have shown either evidence for tumor recurrence or progression by CT or (preferably) MRI scan performed within 21 days prior to registration or had biopsy proven recurrent glioma within the last 12 weeks prior to enrollment (in order to allow the enrollment of patients with recurrent gliomas who have undergone a complete radiographic resection and now have no radiographic evaluable disease) - Patients having undergone recent resection of a recurrent or progressive tumor will be eligible two weeks after surgery. - Patient must have failed prior radiation therapy and must have an interval of greater than or equal to 2 weeks from the completion of radiation therapy to study entry. - All patients must sign an informed consent, or if cognitively impaired, their assigned DPA, indicating that they are aware of the investigational nature of this study. - Patients must be > 18 years old, and must have a life expectancy > 8 weeks. - Patients must have a Karnofsky performance status of > 60. - Additionally, patients must be at least 6 weeks from nitrosoureas, 4 weeks from temozolomide or carboplatin, 3 weeks from procarbazine, and 2 weeks from last vincristine administration. Patients must be at least 4 weeks from other cytotoxic therapies not listed above and 2 weeks for non-cytotoxic agents (e.g., interferon, tamoxifen). - Patients must have adequate bone marrow function (granulocyte count >= 1500/mm3, platelet count of > 100,000/mm3, and hemoglobin > 8 gm%), adequate liver function (total bilirubin <= 1.5 mg/dL, AST/ALT <= 2 x ULN), and adequate renal function (creatinine <= 1.5 mg/dL or creatinine clearance > 60 cc/min) before starting therapy. These tests must be performed within 14 days prior to registration. Eligibility level for hemoglobin may be reached by transfusion. Eligibility level for platelets may not be reached by transfusion. - Patients must either not be receiving steroids, or be on a stable dose of steroids for at least five days prior to registration. - Patients with a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix) are ineligible, unless they are in complete remission and off all therapy for that disease for a minimum of 3 years. - Patients must not be pregnant or nursing, and all patients (both men and women) must be willing to practice birth control during and for 2 months after treatment with CC-8490. Women of childbearing potential (WCBP) who are sexually active must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner). - Patients must be able to swallow capsules whole. Exclusion Criteria: - Patients who, in the view of the treating physician, have significant active cardiac, hepatic, renal, or psychiatric diseases that would significantly increase the risk of using CC-8490 are ineligible. - Concurrent use of other standard chemotherapeutics or investigative agents. - Pregnant or lactating females. - Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study, obscures the evaluation of toxicity or alters drug metabolism. - Use of other experimental study drug within 28 days of registration.
Total Enrollment: 36
Location and Contact Information:
Neuro Oncology Branch National Cancer Institute *Recruiting*
Bethesda, Maryland, 20892-8200
United States
Recruiting Sandra Mitchell 301-402-3435
Additional Information:
Study ID Numbers: CC-8490-GLIO-001;
Study Start Date: December 2003
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00074646
Other Glioblastoma Studies:
1. Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas
Related Studies:
Other Glioblastoma Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas
|
|
|
|
|
|
|
|
